The COSMIC-312 study: will it shape future combination therapies for advanced hepatocellular carcinoma?
- PMID: 38364833
- DOI: 10.1016/S2468-1253(24)00007-4
The COSMIC-312 study: will it shape future combination therapies for advanced hepatocellular carcinoma?
Conflict of interest statement
AS reports consulting fees from Eisai and MSD; speaker fees from BMS, Roche, Servier, Ipsen, Lilly, AstraZeneca, and MSD; and travel support from Ipsen, Servier, Pierre-Fabre, MSD, and Eisai. AL reports consulting fees from Advanz Pharma, AlfaSigma, Takeda, Ipsen, and GSK; speaker fees from Gilead, GSK, AbbVie, MSD, Advanz Pharma, AlfaSigma, GSK, and Incyte; and travel support from Ipsen.
Comment on
-
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.Lancet Gastroenterol Hepatol. 2024 Apr;9(4):310-322. doi: 10.1016/S2468-1253(23)00454-5. Epub 2024 Feb 13. Lancet Gastroenterol Hepatol. 2024. PMID: 38364832 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
